TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7016802

Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 30663168

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir/Voxilaprevir
Number of subjects: 31
Study: 30474011

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) by 120 seconds
Number of subjects: 100

Group type: COMPARATOR
Intervention: Early cord clamping (ECC) within less than 30 seconds
Number of subjects: 100
Study: 26014600

Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (a‐tDCS) during cognitive training
Number of subjects: 20

Group type: COMPARATOR
Intervention: sham tDCS during cognitive training
Number of subjects: 20
Study: 24380397

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) with tenofovir/emtricitabine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Efavirenz (EFV) with tenofovir/emtricitabine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both LPV/r and EFV
Number of subjects: 50
Study: 21997432

Group type: EXPERIMENTAL
Intervention: Transvaginal appendectomy (TVA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 42
Study: 19267384

Group type: EXPERIMENTAL
Intervention: Decision-support intervention for Black women with breast cancer, including in-person sessions, communication skills training, and sharing personal stories
Number of subjects: 34
Study: 17609401

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (administered every 14 days for 12 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (healthy females)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 10
Study: 16215191

Group type: EXPERIMENTAL
Intervention: Workplace fundamentals program (skills training)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 35
Study: 11247010

Group type: EXPERIMENTAL
Intervention: Resting hand splints
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Light tech augmentative communication systems (voice-output devices and symbols)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Very basic parent training
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Familiar storybook reading
Number of subjects: 6

Group type: COMPARATOR
Intervention: Unfamiliar storybook reading
Number of subjects: 6
Study: 9599853

Group type: EXPERIMENTAL
Intervention: Self-help booklet with midwife counselling
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: New magazine-style smoking cessation booklet
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 336
Study: 7974298

Group type: EXPERIMENTAL
Intervention: Menthol 75% in eucalyptus oil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (pine oil or air)
Number of subjects: 20
Study: 2689986

Group type: EXPERIMENTAL
Intervention: F 1.8 formula (1.8 g protein/100 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: F 1.3 formula (1.3 g protein/100 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Breast-fed (BF)
Number of subjects: 30
Study: 30535101

Group type: EXPERIMENTAL
Intervention: SparkPeople plus activity tracker, Fitbit Charge (n = 18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fitbit only (wait-list active control group, n = 17)
Number of subjects: 35
Study: 30241706

Group type: EXPERIMENTAL
Intervention: HHHF intervention (16-week home environment-focused coaching)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: HHHF intervention
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control (health education materials by mail)
Number of subjects: 349
Study: 28005623

Group type: EXPERIMENTAL
Intervention: HAED
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAPER
Number of subjects: 0
Study: 26025767

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1240
Study: 23197590

Group type: EXPERIMENTAL
Intervention: Moderate fortification (MF)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Aggressive fortification (AF)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard fortification (SF)
Number of subjects: 84
Study: 22333250

Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (CNI)
Number of subjects: 74
Study: 19358498

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment at Tinghui (GB 2), Yifeng (TE 17), Hegu (LI 4), Xiaxi (GB 43), Zhongzhu (TE 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group with intravenous 6% low molecule dextran 500 mL with ATP and coenzyme A, and oral Nimodipine, Gold Theragan
Number of subjects: 60
Study: 16935718

Group type: EXPERIMENTAL
Intervention: Low-dose CT scans at 15 mA
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT scans (tube current < 15 mA) with edge-preserving smoothing filter
Number of subjects: 5

Group type: COMPARATOR
Intervention: High-dose CT scans (55 mA)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Low-dose CT scans
Number of subjects: 5
Study: 15568948

Group type: EXPERIMENTAL
Intervention: Optical coherence microscopy (OCM)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Confocal microscopy
Number of subjects: 13
Study: 11766661

Group type: EXPERIMENTAL
Intervention: Ropivacaine instillation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control (no ropivacaine instillation)
Number of subjects: 118
Study: 9764629

Group type: EXPERIMENTAL
Intervention: Oral HRT
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 63
Study: 8310977

Group type: EXPERIMENTAL
Intervention: Amlodipine (mean daily dose 8.8 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Atenolol (mean daily dose 83.7 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 2897780

Group type: EXPERIMENTAL
Intervention: bevantolol (200 to 400 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: atenolol (50 to 100 mg)
Number of subjects: 39
Study: 29433430

Group type: EXPERIMENTAL
Intervention: Switch to second-line ART immediately
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (not switched) according to WHO guidelines
Number of subjects: 80
Study: 28110896

Group type: EXPERIMENTAL
Intervention: mepolizumab 75 mg IV
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg SC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: mepolizumab 75 mg IV and SC
Number of subjects: 50
Study: 26144571

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24094008

Group type: EXPERIMENTAL
Intervention: Lingual arch for space maintenance (n = 30)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group with no orthodontic treatment (n = 14)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison between EG and CG
Number of subjects: 44
Study: 21507573

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation
Number of subjects: 214

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group (treatment-as-usual)
Number of subjects: 214
Study: 18499007

Group type: EXPERIMENTAL
Intervention: AquaLase liquefaction cataract surgery
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ultrasound (US) phacoemulsification cataract surgery
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: AquaLase liquefaction cataract surgery (subgroup analysis of diabetic patients)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ultrasound (US) phacoemulsification cataract surgery (subgroup analysis of diabetic patients)
Number of subjects: 63
Study: 16510488

Group type: EXPERIMENTAL
Intervention: MDMA/THC users
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: THC users
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-drug users
Number of subjects: 41
Study: 12395616

Group type: EXPERIMENTAL
Intervention: Median nerve compression test (MNCT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no MNCT)
Number of subjects: 18
Study: 10446869

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 46
Study: 7576676

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 39

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 39
Study: 2107060

Group type: EXPERIMENTAL
Intervention: Niflumic acid (4 capsules of 250 mg daily)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 35189

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6626105

Group type: EXPERIMENTAL
Intervention: Partner-assisted exposure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Self-controlled exposure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Self-controlled exposure (Post-treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both conditions (6-month follow-up)
Number of subjects: 12
Study: 31501084

Group type: EXPERIMENTAL
Intervention: early salvage radiotherapy (eSRT) initiated at PSA <0.5 ng/ml
Number of subjects: 1458

Group type: COMPARATOR
Intervention: late salvage radiotherapy (lSRT) initiated at PSA ≥0.5 ng/ml
Number of subjects: 1458
Study: 30345498

Group type: EXPERIMENTAL
Intervention: Classic Obturator Nerve Block (ONB)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Inguinal Obturator Nerve Block (ONB)
Number of subjects: 66
Study: 29847486

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target SBP < 120 mmHg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Modest blood pressure control (target SBP < 140 mmHg)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 132
Study: 26515607

Group type: EXPERIMENTAL
Intervention: Long-acting paliperidone palmitate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-acting haloperidol decanoate
Number of subjects: 0
Study: 25286782

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MS)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 22229677

Group type: EXPERIMENTAL
Intervention: ECMO intervention
Number of subjects: 10
Study: 20102927

Group type: EXPERIMENTAL
Intervention: RV TDI systolic velocity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Digoxin treatment
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Transmitral Doppler to mitral annular TDI early diastolic velocity ratio
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: RV TDI early diastolic velocity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ratio of early to late RV diastolic TDI velocities
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Decreased RV systolic velocity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Increased ratio of early to late RV diastolic TDI velocities
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Increased BNP
Number of subjects: 102
Study: 17592238

Group type: EXPERIMENTAL
Intervention: Flat fitting group (R1 > R2)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Steep fitting group (R1 < R2)
Number of subjects: 47
Study: 16247225

Group type: EXPERIMENTAL
Intervention: Power Doppler ultrasound-guided target biopsy
Number of subjects: 302

Group type: COMPARATOR
Intervention: Sextant biopsy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Combined PDU and sextant biopsy
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Target biopsy
Number of subjects: 302
Study: 12385435

Group type: EXPERIMENTAL
Intervention: B-LAC (bismuth, clarithromycin, amoxicillin, and lansoprazole)
Number of subjects: 56

Group type: COMPARATOR
Intervention: B-LAA (bismuth, azithromycin, amoxicillin, and lansoprazole)
Number of subjects: 56
Study: 10442379

Group type: EXPERIMENTAL
Intervention: Endocrine plus UFT therapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Endocrine-only therapy
Number of subjects: 136
Study: 7605858

Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg/day for 10 weeks, tapered to 6 mg/day after 8 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg/day for 10 weeks, tapered to 5 mg/day after 2 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both treatments (Budesonide and Prednisolone)
Number of subjects: 18
Study: 2192700

Group type: EXPERIMENTAL
Intervention: ioversol-240
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ioversol-320
Number of subjects: 0
Study: 498413

Group type: EXPERIMENTAL
Intervention: Daunorubicin (1.0‐1.5 mg/kg) as the free drug (for 45 min or 4 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Daunorubicin bound to a DNA carrier (for 5‐6 h)
Number of subjects: 15
Study: 31227307

Group type: EXPERIMENTAL
Intervention: Immediate cytoreductive nephrectomy (CN) followed by sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib followed by deferred CN 24h after the last dose of sunitinib
Number of subjects: 0
Study: 28202686

Group type: EXPERIMENTAL
Intervention: Simvastatin pre-treatment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Simvastatin post-treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (vehicle alone)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Simvastatin pre-treatment and post-treatment
Number of subjects: 72
Study: 25851020

Group type: EXPERIMENTAL
Intervention: Ropivacaine infusion via saphenous catheter
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isotonic saline infusion via saphenous catheter
Number of subjects: 50
Study: 24070181

Group type: EXPERIMENTAL
Intervention: Structured diabetes and hypertension clinical record (SR) introduced in intervention clinics after training doctors.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no SR implementation).
Number of subjects: 60
Study: 20842754

Group type: EXPERIMENTAL
Intervention: Ginger root powder capsules
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study: 19235038

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25-OH-VitD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH)
Number of subjects: 0
Study: 17490569

Group type: EXPERIMENTAL
Intervention: Soluvit treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (500 ml normal saline infusion)
Number of subjects: 87
Study: 15472178

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.074 mg/kg, administered subcutaneously three times per week until height velocity decreased to less than 1.5 cm/year
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo, administered subcutaneously three times per week until height velocity decreased to less than 1.5 cm/year
Number of subjects: 68
Study: 12042081

Group type: EXPERIMENTAL
Intervention: Peer-led HIV prevention programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer education programme
Number of subjects: 0
Study: 9854471

Group type: EXPERIMENTAL
Intervention: Image Cytometry DNA analysis
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: p53 and p21/WAF1 evaluation
Number of subjects: 21
Study: 7828383

Group type: EXPERIMENTAL
Intervention: Simvastatin treatment for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 2132641

Group type: EXPERIMENTAL
Intervention: Actovegin (250 ml 20%)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 527635

Group type: EXPERIMENTAL
Intervention: Codeine 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Noscapine 30 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30873102

Group type: EXPERIMENTAL
Intervention: rMV (vibration group–VG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham treatment (control group–CG)
Number of subjects: 22
Study: 29996204

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r plus DSV for 12 weeks (Group A)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo for 12 weeks (Group B)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: OBV/PTV/r plus DSV after placebo in open-label phase (Group B)
Number of subjects: 410
Study: 27846927

Group type: COMPARATOR
Intervention: Standard health check invitation only
Number of subjects: 12459

Group type: EXPERIMENTAL
Intervention: QBE questionnaire followed by a standard invitation
Number of subjects: 12459

Group type: EXPERIMENTAL
Intervention: QBE questionnaire with offer of a financial incentive to return the questionnaire, followed by a standard invitation
Number of subjects: 12459

Group type: COMPARATOR
Intervention: Opportunistic health checks
Number of subjects: 12459
Study: 25156453

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 17
Study: 22086510

Group type: EXPERIMENTAL
Intervention: Long-axis needle guide (NG)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Long-axis free hand (L-FH)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Short-axis free hand (S-FH)
Number of subjects: 33
Study: 20638463

Group type: EXPERIMENTAL
Intervention: N-Acetyl-cysteine (NAC) 1200 mg/day for 14 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 17938371

Group type: EXPERIMENTAL
Intervention: Lamotrigine XR
Number of subjects: 239
Study: 15269313

Group type: EXPERIMENTAL
Intervention: Cetuximab plus irinotecan
Number of subjects: 329

Group type: COMPARATOR
Intervention: Cetuximab monotherapy
Number of subjects: 329
Study: 11673326

Group type: EXPERIMENTAL
Intervention: Writing with the right hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Writing with the left hand
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 0
Study: 9751064

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (1000 microg/day)
Number of subjects: 10
Study: 7870548

Group type: EXPERIMENTAL
Intervention: Throwing paddleball in noise conditions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Throwing paddleball in quiet conditions
Number of subjects: 56
Study: 3416617

Group type: EXPERIMENTAL
Intervention: Soft contact lenses under low luminance and contrast conditions
Number of subjects: 4

Group type: COMPARATOR
Intervention: Spectacles under low luminance and contrast conditions
Number of subjects: 4
Study: 29520944

Group type: EXPERIMENTAL
Intervention: Teethmate AP (TAP) desensitizer paste
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both TAP and PLA
Number of subjects: 50
Study: 28479257

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) with a bridge of 30 mL of 0.5% bupivacaine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Indwelling interscalene nerve block (IINB)
Number of subjects: 83
Study: 24535359

Group type: EXPERIMENTAL
Intervention: dezocine (0.1 mg/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: flurbiprofen axetil (1 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: control group (physiological saline)
Number of subjects: 90
Study: 23063354

Group type: EXPERIMENTAL
Intervention: FLOT (infusional 5‐FU, leucovorin, oxaliplatin, and docetaxel 50 mg/m(2))
Number of subjects: 143

Group type: COMPARATOR
Intervention: FLO (infusional 5‐FU, leucovorin, and oxaliplatin)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: FLOT
Number of subjects: 143

Group type: COMPARATOR
Intervention: FLO
Number of subjects: 143
Study: 20739846

Group type: EXPERIMENTAL
Intervention: Adjuvant interferon (IFN) therapy
Number of subjects: 1769

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1769
Study: 18379536

Group type: EXPERIMENTAL
Intervention: AA-containing peritoneal dialysis solution
Number of subjects: 13
Study: 16391217

Group type: EXPERIMENTAL
Intervention: L-arginine (3 g 3 times a day for 6 months)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 12604748

Group type: EXPERIMENTAL
Intervention: Alzheimer's Association care consultation service
Number of subjects: 157
Study: 10806282

Group type: EXPERIMENTAL
Intervention: lovastatin (20 mg)
Number of subjects: 209

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 209
Study: 10163928

Group type: EXPERIMENTAL
Intervention: Jet spacer device (MDI with Jet spacer)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard actuator (MDI with standard actuator)
Number of subjects: 36
Study: 8274805

Group type: EXPERIMENTAL
Intervention: Low-activity group (physically inactive subjects)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Children with disk protrusion
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 76
Study: 3020700

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/doxorubicin/etoposide (CAE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide/doxorubicin/vincristine (CAV)
Number of subjects: 0
Study: 29894467

Group type: EXPERIMENTAL
Intervention: Masseter muscle injection with type A botulinum toxin
Number of subjects: 8

Group type: COMPARATOR
Intervention: No masseter muscle injection with type A botulinum toxin (Control)
Number of subjects: 8
Study: 27178854

Group type: EXPERIMENTAL
Intervention: 10Hz rTMS to S2
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 57
Study: 25922111

Group type: EXPERIMENTAL
Intervention: 4-week maximal isokinetic training of the stronger ankle dorsiflexors at 90°/s
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 30
Study: 23579106

Group type: EXPERIMENTAL
Intervention: Active NMES
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Passive NMES
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (sham stimulation)
Number of subjects: 31